Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
VistaGen Therapeutics, Inc. VTGN
$0.14
-$0 (-1.26%)
На 18:01, 12 мая 2023
+42.86%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
31407483.00000000
-
week52high
1.25
-
week52low
0.08
-
Revenue
1108900
-
P/E TTM
0
-
Beta
0.99826900
-
EPS
-0.32000000
-
Last Dividend
0.00000000
-
Next Earnings Date
21 июн 2023 г. в 10:59
Описание компании
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Maxim Group | Hold | Buy | 26 июл 2022 г. |
| William Blair | Market Perform | Outperform | 22 июл 2022 г. |
| Baird | Outperform | 20 мая 2021 г. | |
| Jefferies | Buy | 18 февр 2021 г. | |
| William Blair | Outperform | Market Perform | 04 янв 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Singh Shawn | A | 158998 | 5000 | 30 дек 2022 г. |
| DOTSON JERROLD DUANE | A | 105111 | 5000 | 30 дек 2022 г. |
| GIN JERRY B | A | 100000 | 100000 | 18 авг 2022 г. |
| Adler Reid G. | A | 334629 | 300000 | 17 авг 2022 г. |
| Singh Shawn | A | 626234 | 600000 | 17 авг 2022 г. |
| DOTSON JERROLD DUANE | A | 100111 | 5000 | 30 июл 2022 г. |
| Venrock Healthcare Capital Partners II, L.P. | D | 20637286 | 60000 | 12 июл 2022 г. |
| Smith Mark Alan | A | 19915 | 5000 | 30 июн 2022 г. |
| Singh Shawn | A | 153998 | 5000 | 30 июн 2022 г. |
| Singh Shawn | D | 70000 | 100000 | 12 мая 2022 г. |
Новостная лента
What to Look For When Finding Penny Stocks to Buy, 3 Tips
PennyStocks
23 мар 2023 г. в 06:00
Use these tips for finding penny stocks to buy in 2023 The post What to Look For When Finding Penny Stocks to Buy, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
VistaGen Therapeutics, Inc. (VTGN) Q3 2023 Earnings Call Transcript
Seeking Alpha
10 февр 2023 г. в 11:20
VistaGen Therapeutics, Inc. (NASDAQ:VTGN ) Q3 2023 Earnings Conference Call February 7, 2023 5:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Executive Officer Jerrold Dotson - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies LLC Timothy Lugo - William Blair & Company LLC Operator Greetings. Welcome to VistaGen Therapeutics Third Quarter Fiscal Year 2023 Results Conference Call.
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research
07 февр 2023 г. в 19:34
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 16.67% and 41.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
Business Wire
06 февр 2023 г. в 09:09
SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Tuesday, February 7, 2023, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report financial results for its fiscal year 2023 third quarter ended December 31, 2022 and provide a corporate update.
The 3 Biggest Impacts on Penny Stocks Prices
PennyStocks
01 февр 2023 г. в 06:00
These factors are the main causes of penny stocks price movement The post The 3 Biggest Impacts on Penny Stocks Prices appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.